Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 61 results for early and locally advanced breast cancer

  1. Effectivness of 26 Gy in 5 fractions over 1 week regimen in people receiving breast construction- What is the effectiveness of radiotherapy given in 26 Gy in 5 fractions over 1 week compared with 40 Gy in 15 fractions over 3 weeks in people with early or locally advanced invasive breast cancer who are offered breast reconstruction?

    Effectivness of 26 Gy in 5 fractions over 1 week regimen in people receiving breast construction- What is the effectiveness of...

    Research recommendation
    Published
    7 August 2023

  2. MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)

    NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .

    Medtech innovation briefing
    Published
    18 January 2018

  3. Efectiveness of 26 Gy in 5 fractions over 1 week regimen in people receiving nodal irradiation- What is the effectiveness of radiotherapy given in 26 Gy in 5 fractions over 1 week compared with 40 Gy in 15 fractions over 3 weeks in people with early or locally advanced invasive breast cancer who are also offered nodal irradiation?

    with 40 Gy in 15 fractions over 3 weeks in people with early or locally advanced invasive breast...

    Research recommendation
    Published
    7 August 2023

  4. Neoadjuvant endocrine therapy in premenopausal women:- Is neoadjuvant endocrine therapy safe in premenopausal women with early breast cancer?

    women:- Is neoadjuvant endocrine therapy safe in premenopausal women with early breast cancer? Any explanatory...

    Research recommendation
    Published
    11 December 2018

  5. Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

    Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children over 12 years.

    Technology appraisal guidance
    Published
    12 August 2020
    View recommendations

    Sections for TA644

  6. Neoadjuvant endocrine therapy in postmenopausal women:- Is there a benefit for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer?

    benefit for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer? Any explanatory...

    Research recommendation
    Published
    11 December 2018

  7. Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)

    NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .

    Medtech innovation briefing
    Published
    4 October 2022

  8. Surgery to the breast:- What is the optimum tumour-free margin width after breast-conserving surgery for women with ductal carcinoma in situ (DCIS) and invasive breast cancer?

    NG101/1 Question Surgery to the breast:- What is the optimum tumour-free margin width after breast-conserving surgery for...

    Research recommendation
    Published
    11 December 2018

  9. What is the adherence to, and satisfaction with, different intervention formats (for example, individual, group, virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the impact of greater adherence on effectiveness for different groups, such as: women, men, trans people and non-binary people people from minority ethnic family backgrounds people with learning disabilities or cognitive impairment, or physical disabilities, or both neurodiverse people?

    virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the...

    Research recommendation
    Published
    7 August 2023

  10. What is the adherence to, and satisfaction with, different intervention formats (for example, individual, group, virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the impact of greater adherence on effectiveness for different groups, such as: women, men, trans people and non-binary people people from minority ethnic family backgrounds people with learning disabilities or cognitive impairment, or physical disabilities, or both neurodiverse people?

    virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the...

    Research recommendation
    Published
    5 May 2023

  11. What is the most effective and cost-effective way of delivering the intervention (for example, type of physiotherapy or exercise, mode of delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the acceptability of the intervention for different groups, such as: women, men, trans people and non-binary people people from minority ethnic family backgrounds people with learning disabilities or cognitive impairment, or physical disabilities, or both neurodiverse people?

    delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is...

    Research recommendation
    Published
    5 May 2023

  12. Strategies to reduce arm and shoulder problems- What is the most effective and cost-effective way of delivering the intervention (for example, type of physiotherapy or exercise, mode of delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the acceptability of the intervention for different groups, such as: women, men, trans people and non-binary people people from minority ethnic family backgrounds people with learning disabilities or cognitive impairment, or physical disabilities, or both neurodiverse people?

    delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is...

    Research recommendation
    Published
    7 August 2023

  13. Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

    Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.

    Technology appraisal guidance
    Published
    27 May 2020
    View recommendations

    Sections for TA630

  14. Breast reconstruction:- What are the long-term outcomes for breast reconstruction in women having radiotherapy to the chest wall?

    Recommendation ID NG101/3 Question Breast reconstruction:- What are the long-term outcomes for breast reconstruction in...

    Research recommendation
    Published
    11 December 2018

  15. Neoadjuvant treatment:- What are the indications for postmastectomy radiotherapy after neoadjuvant chemotherapy?

    Source guidance details Comes from guidance Early and locally advanced breast cancer: diagnosis and management Number NG101

    Research recommendation
    Published
    11 December 2018